Geron Corp.
GERN
Get informed when a big investor buys or sells
+ FollowMarket Cap$719.57M
Close$
$-0.03
103.1% downside
Current Fair Value
103.1% downsideOvervalued by 103.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $719.57 Million |
|---|---|
| Enterprise Value | $779.07 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.13 |
| Beta | 0.61 |
| Outstanding Shares | 670,696,000 |
Return
| Return on Equity | -31.97% |
|---|---|
| Return on Assets | -13.47% |
| Return on Invested Capital | -7.33% |
Valuation & Multiples
| P/E Ratio | -11.23 |
|---|---|
| PEG | -603.12 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 3.81 |
| Enterprise Value to EBIT | -23.68 |
| Enterprise Value to Net Income | -12 |
| Total Debt to Enterprise | 0.16 |
| Debt to Equity | 0.56 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$-0.01
Average shareholder expectationRevenue Estimate
$55.30 M
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$-0.01
Average shareholder expectationRevenue Estimate
$60.35 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 179.72% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.01%▼ 71.69% |
|---|---|
| Total Invested | $122,255▼ 99.98% |
| Investors Holding | 4▼ 263.00% |
ESG Score
No data
About Geron Corp.
258 employees
CEO: John Scarlett Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients...